RPA1 and malignant colon neoplasm: Further studies are required to investigate the potential of RPA1 and HSPA5/GRP78 in the real-world setting using clinical samples and to examine their roles in determining cancer cell response to BRAFV600E inhibition, not only in colon cancer but also in other BRAFV600E-mutated cancers.